Novo Nordisk plans to slash US list prices for Wegovy and Ozempic by up to half starting next year
Novo Nordisk will reduce monthly costs for its popular weight-loss and diabetes treatments to $675 in 2027. The move aims to improve patient affordability.
Insights:
Novo Nordisk A/S announced on February 24, 2026, that it will reduce the list prices for its GLP-1 medicines in the United States 
US by up to 50 percent. The price reductions, which apply to Ozempic, Wegovy, and Rybelsus, are scheduled to take effect on January 1 next year. This announcement from the pharmaceutical company, which is headquartered in Denmark 
DK, coincides with the implementation of newly lower Medicare prices.
US by up to 50 percent. The price reductions, which apply to Ozempic, Wegovy, and Rybelsus, are scheduled to take effect on January 1 next year. This announcement from the pharmaceutical company, which is headquartered in Denmark DK, coincides with the implementation of newly lower Medicare prices.
